a Department "G.F. Ingrassia"; MS center , University of Catania , Catania , Italy.
b Department of Economy , University of Messina , Messina , Italy.
Expert Opin Pharmacother. 2019 Aug;20(11):1331-1340. doi: 10.1080/14656566.2019.1615880. Epub 2019 May 15.
: Recently, the economic impact of multiple sclerosis (MS), which includes both direct and indirect costs, has been increasing. While direct costs comprise health-care costs, such as the cost of pharmaceuticals, additional treatments such as physiotherapy, and medical aids, indirect costs are triggered by the productivity loss of patients and caregivers. Although new drugs for MS have changed the therapeutic scenario, they have increased the direct costs of health-care services. : This review describes the pharmacoeconomic aspects of synthetic therapies for MS. Additionally, it discusses the economic impact of the various classes of licensed disease-modifying treatments (DMTs) for relapsing forms of MS. : The emerging and more expensive DMTs for MS represent a considerable challenge for health-care systems and resource consumption. Future research should focus on the long-term efficacy of DMTs and the cost of treating MS in a real-life setting. Future biological and radiological biomarkers could help stratify patients at early stages of MS, helping physicians design a personalized therapeutic approach that could have a positive impact in economic terms.
: 多发性硬化症（MS）的经济影响（包括直接和间接成本）近来一直在增加。直接成本包括药品成本等医疗保健费用，以及物理治疗等额外治疗和医疗辅助器具；间接成本则由患者和护理人员的生产力损失引发。尽管用于 MS 的新药改变了治疗前景，但它们增加了医疗服务的直接成本。: 本文综述了多发性硬化症的合成疗法的药物经济学方面，还讨论了各种获批的用于缓解复发型 MS 的疾病修正治疗（DMT）药物的经济影响。: 新兴且更为昂贵的 MS 治疗药物给医疗体系和资源消耗带来了巨大挑战。未来的研究应关注 DMT 的长期疗效和现实环境下治疗 MS 的成本。未来的生物和放射学生物标志物可以帮助在 MS 的早期阶段对患者进行分层，帮助医生设计个性化的治疗方法，从而在经济方面产生积极影响。
